ARTICLE | Company News
RegenxBio, Biogen deal
May 23, 2016 7:00 AM UTC
RegenxBio granted Biogen exclusive, worldwide rights to RegenxBio’s NAV adeno-associated virus (AAV) AAV8 and AAV9 vectors for achromotopsia and choroideremia. RegenxBio will receive an undisclosed up...